ALGS
Aligos Therapeutics, Inc.Company Information
- Company Name
- Aligos Therapeutics, Inc.
- CIK
- CIK0001799448
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ALGS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ALGS
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-10-25
- Last sale
- —
- Shares purchased (TTM)
- 7,933,601
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,292,538
- Shares outstanding
- 10,430,808
- Ownership
- 21.98%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 25.41%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Assets Current | 62 | 60 | 83 | 103 | 128 | 143 | 62 | 80 | 100 | 118 | 141 | 75 | ||||||
| Cash And Cash Equivalents At Carrying Value | 30 | 30 | 18 | 42 | 19 | 74 | 37 | 35 | 45 | 24 | 136 | 70 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Short Term Investments | 0 | 25 | 60 | 57 | 104 | 64 | 20 | 40 | 49 | 89 | - | - | ||||||
| Accounts Receivable Net Current | 28 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Current | 4 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | ||||||
| Operating Lease Right Of Use Asset | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | ||||||
| Property Plant And Equipment Net | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 66 | 65 | 89 | 110 | 135 | 151 | 70 | 88 | 109 | 128 | 152 | 86 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 6 | 8 | 4 | 5 | 4 | 4 | 3 | 3 | 7 | 3 | 3 | 3 | ||||||
| Accrued Liabilities Current | 19 | 12 | 14 | 14 | 12 | 11 | 16 | 14 | 12 | 12 | 17 | 12 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 28 | 23 | 21 | 22 | 20 | 19 | 22 | 21 | 24 | 19 | 24 | 22 | ||||||
| Operating Lease Liability Current | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue Current | - | - | 0 | 0 | 1 | - | 0 | - | - | - | 1 | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 1 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 7 | 8 | 8 | ||||||
| Finance Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 34 | 33 | 35 | 38 | 33 | 34 | 99 | 38 | 42 | 68 | 59 | 31 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 698 | 697 | 695 | 694 | 692 | 691 | 589 | 585 | 583 | 581 | 578 | 513 | ||||||
| Stockholders Equity | 32 | 32 | 54 | 72 | 102 | 116 | -29 | 50 | 67 | 60 | 92 | 55 | ||||||
| Retained Earnings Accumulated Deficit | -667 | -665 | -642 | -622 | -591 | -575 | -618 | -536 | -517 | -522 | -487 | -459 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | ||||||
| Liabilities And Stockholders Equity | 66 | 65 | 89 | 110 | 135 | 151 | 70 | 88 | 109 | 128 | 152 | 86 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 116 | 116 | 116 | 116 | 116 | 21 | 21 | 21 | 520 | 320 | 13 | 320 | ||||||
| Common Stock Shares Issued | 6 | 6 | 6 | 6 | 6 | 6 | 4 | 3 | 3 | 3 | 3 | 1 | ||||||
| Shares Outstanding | 6 | 6 | 6 | 6 | 6 | 6 | 4 | 80 | 3 | 3 | 3 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAligos Therapeutics, Inc. (ALGS) — SEC Financial Statements & Analysis
Aligos Therapeutics, Inc. (ALGS) is a biological products, (no diagnostic substances) company, incorporated in DE. Aligos Therapeutics, Inc. trades on Nasdaq as: ALGS. Aligos Therapeutics, Inc. (ALGS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Aligos Therapeutics, Inc. carries a market cap of $60.19M, a P/E ratio of -0.79x, a P/B ratio of 1.89x, a P/S ratio of 16.09x, an enterprise value of $29.83M, and an EV/EBITDA multiple of -0.38x. On profitability, it posts an operating margin of -2112.14%, a net margin of -2031.07%, a Return on Equity (ROE) of -113.59%, a Return on Assets (ROA) of -75.57%, and a Return on Invested Capital (ROIC) of -186.05%. Per share, it reports EPS of $-7.28, diluted EPS of $-7.28, free cash flow per share of $-9.03, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 19.41% year-over-year, net income growth of 2.40% year-over-year, and EPS growth of 1.61% year-over-year. On the balance sheet, it maintains a current ratio of 2.19x, a quick ratio of 2.19x, working capital of $33.78M, a debt-to-equity ratio of 1.08x, a debt ratio of 0.52, free cash flow of $-94.17M (TTM), and net debt of $-30.36M. Figures sourced from SEC EDGAR.
- Market Cap
- $60.19M
- P/E TTM
- -0.79x
- EPS TTM
- $-7.28
- P/B TTM
- 1.89x
- ROE TTM
- -113.59%
- ROA TTM
- -75.57%
- Debt To Equity
- 1.08x
- Free Cash Flow TTM
- $-94.17M
- Net Revenue TTM Growth 1Y
- 19.41%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aligos Therapeutics, Inc. in?
Aligos Therapeutics, Inc. (ALGS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ALGS trade on?
Aligos Therapeutics, Inc. (ALGS) trades on the Nasdaq.
Where is Aligos Therapeutics, Inc. incorporated?
Aligos Therapeutics, Inc. is incorporated in DE.
When was Aligos Therapeutics, Inc. (ALGS)'s most recent SEC filing?
Aligos Therapeutics, Inc. (ALGS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ALGS's market cap?
Aligos Therapeutics, Inc. (ALGS) has a market capitalization of $60.19M as of 2026-06-30.
What is ALGS's EPS (earnings per share)?
Aligos Therapeutics, Inc. (ALGS)'s trailing twelve month EPS is $-7.28 as of 2026-06-30.
What is ALGS's ROE (return on equity)?
Aligos Therapeutics, Inc. (ALGS)'s trailing twelve month Return on Equity (ROE) is -113.59% as of 2026-06-30.
What is ALGS's ROA (return on assets)?
Aligos Therapeutics, Inc. (ALGS)'s trailing twelve month Return on Assets (ROA) is -75.57% as of 2026-06-30.
What is ALGS's ROIC (return on invested capital)?
Aligos Therapeutics, Inc. (ALGS)'s trailing twelve month Return on Invested Capital (ROIC) is -186.05% as of 2026-06-30.
What is ALGS's EV/EBITDA?
Aligos Therapeutics, Inc. (ALGS)'s trailing twelve month EV/EBITDA is -0.38x as of 2026-06-30.